Mario Balsa/X
Jun 1, 2025, 11:35
Mario Balsa: Breaking from ASCO 2025 – DESTINY-Gastric04 Trial
Mario Balsa, Medical Oncology resident at ICO, Shared a post on X:
“Breaking from ASCO25 — DESTINY-Gastric04
T-DXd outperforms RAM+PTX in 2L HER2+ advanced G/GEJ cancer:
mOS: 14.7 vs 11.4 mo (HR: 0.70, p=0.004)
mPFS: 6.7 vs 5.6 mo
cORR: 44.3% vs 29.1%
DCR: 91.9% vs 75.9%A new standard? Eureka, you found it.”
Read OncoDaily’s Special Articles about ASCO25:
Highlights from ASCO 2025 Day 1
Highlights from ASCO 2025 Day 2
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 16, 2025, 17:55
Jul 16, 2025, 17:38
Jul 16, 2025, 17:37
Jul 16, 2025, 17:04
Jul 16, 2025, 16:51
Jul 16, 2025, 16:34
Jul 16, 2025, 16:18